biostudies-literatureMidorikawa RFujirebioAstellas Pharma Inc.National Hospital OrganizationMitsubishi Tanabe Pharma CorporationTakeda Pharmaceutical Company Limited965https://www.ebi.ac.uk/biostudies/studies/S-EPMC9144302biostudies-literatureUnknown14(5)Serological detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid (N), spike (S), and neutralizing antibodies (Abs) is commonly undertaken to evaluate the efficacy of vaccination. However, the relative efficiency of different SARS-CoV-2 Ab detection systems has not been extensively investigated. Here, we evaluated serological test systems in vaccinated Japanese. SARS-CoV-2 N, S, and neutralizing Abs in sera of 375 healthy subjects a mean 253 days after vaccination were assessed. The sensitivity of Elecsys Anti-SARS-CoV-2 S (Roche S) and Anti-SARS-CoV-2 S IgG (Fujirebio S) was 100% and 98.9%, respectively, with a specificity of 100% for both. The sensitivity of Anti-SARS-CoV-2 neutralizing Ab (MBL Neu) was 2.7%, and the specificity was 100%. Fujirebio S correlated with Roche S (rho = 0.9182, <i>p</i> = 3.97 × 10^-152). Fujirebio S (rho = 0.1295, <i>p</i> = 0.0121) and Roche S (rho = 0.1232, <i>p</i> = 0.0170) correlated weakly with MBL Neu. However, Roche S did correlate with MBL Neu in patients with COVID-19 (rho = 0.8299, <i>p</i> = 1.01 × 10^-12) and in healthy subjects more recently after vaccination (mean of 90 days, rho = 0.5306, <i>p</i> = 0.0003). Thus, the Fujirebio S and Roche S results were very similar, but neither correlated with neutralizing antibody titers by MBL Neu at a later time after vaccination.VirusesDetection of SARS-CoV-2 Nucleocapsid, Spike, and Neutralizing Antibodies in Vaccinated Japanese.PMC9144302NAMidorikawa RNagai HNakama MOka SFurukawa HTohma SHiguchi TNagai NfalseDetection of SARS-CoV-2 Nucleocapsid, Spike, and Neutralizing Antibodies in Vaccinated Japanese.Serological detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid (N), spike (S), and neutralizing antibodies (Abs) is commonly undertaken to evaluate the efficacy of vaccination. However, the relative efficiency of different SARS-CoV-2 Ab detection systems has not been extensively investigated. Here, we evaluated serological test systems in vaccinated Japanese. SARS-CoV-2 N, S, and neutralizing Abs in sera of 375 healthy subjects a mean 253 days after vaccination were assessed. The sensitivity of Elecsys Anti-SARS-CoV-2 S (Roche S) and Anti-SARS-CoV-2 S IgG (Fujirebio S) was 100% and 98.9%, respectively, with a specificity of 100% for both. The sensitivity of Anti-SARS-CoV-2 neutralizing Ab (MBL Neu) was 2.7%, and the specificity was 100%. Fujirebio S correlated with Roche S (rho = 0.9182, <i>p</i> = 3.97 × 10^-152). Fujirebio S (rho = 0.1295, <i>p</i> = 0.0121) and Roche S (rho = 0.1232, <i>p</i> = 0.0170) correlated weakly with MBL Neu. However, Roche S did correlate with MBL Neu in patients with COVID-19 (rho = 0.8299, <i>p</i> = 1.01 × 10^-12) and in healthy subjects more recently after vaccination (mean of 90 days, rho = 0.5306, <i>p</i> = 0.0003). Thus, the Fujirebio S and Roche S results were very similar, but neither correlated with neutralizing antibody titers by MBL Neu at a later time after vaccination.2022-01-01T00:00:00Z2022 May2025-04-18T22:59:09.29Z2025-02-19T03:25:15.775ZS-EPMC91443023563271010.3390/v14050965